Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 73

1.

[Progress of research and development of MAPK pathway inhibitors].

Ishii N.

Nihon Yakurigaku Zasshi. 2013 Jan;141(1):15-21. Review. Japanese. No abstract available.

PMID:
23302943
2.

Vemurafenib/dabrafenib and trametinib.

Rissmann R, Hessel MH, Cohen AF.

Br J Clin Pharmacol. 2015 Oct;80(4):765-7. doi: 10.1111/bcp.12651. Epub 2015 Jun 11. No abstract available.

3.

Upstream mitogen-activated protein kinase (MAPK) pathway inhibition: MEK inhibitor followed by a BRAF inhibitor in advanced melanoma patients.

Goldinger SM, Zimmer L, Schulz C, Ugurel S, Hoeller C, Kaehler KC, Schadendorf D, Hassel JC, Becker J, Hauschild A, Dummer R; Dermatology Cooperative Oncology Group (DeCOG).

Eur J Cancer. 2014 Jan;50(2):406-10. doi: 10.1016/j.ejca.2013.09.014. Epub 2013 Oct 29.

PMID:
24183461
4.

Rapid evolution of combination therapy in melanoma.

Curti BD.

N Engl J Med. 2014 Nov 13;371(20):1929-30. doi: 10.1056/NEJMe1411158. No abstract available.

PMID:
25390744
5.

Selective Targeting of CTNBB1-, KRAS- or MYC-Driven Cell Growth by Combinations of Existing Drugs.

Uitdehaag JC, de Roos JA, van Doornmalen AM, Prinsen MB, Spijkers-Hagelstein JA, de Vetter JR, de Man J, Buijsman RC, Zaman GJ.

PLoS One. 2015 May 27;10(5):e0125021. doi: 10.1371/journal.pone.0125021. eCollection 2015. Erratum in: PLoS One. 2015;10(6):e0132230.

6.

Molecular pathways: adaptive kinome reprogramming in response to targeted inhibition of the BRAF-MEK-ERK pathway in cancer.

Johnson GL, Stuhlmiller TJ, Angus SP, Zawistowski JS, Graves LM.

Clin Cancer Res. 2014 May 15;20(10):2516-22. doi: 10.1158/1078-0432.CCR-13-1081. Epub 2014 Mar 24.

7.

MAP-kinase pathway up or down? Just look at the skin of your patients!

Robert C, Thomas M, Mateus C.

Melanoma Res. 2014 Oct;24(5):421-3. doi: 10.1097/CMR.0000000000000114. No abstract available.

PMID:
25185691
8.

Overcoming acquired BRAF inhibitor resistance in melanoma via targeted inhibition of Hsp90 with ganetespib.

Acquaviva J, Smith DL, Jimenez JP, Zhang C, Sequeira M, He S, Sang J, Bates RC, Proia DA.

Mol Cancer Ther. 2014 Feb;13(2):353-63. doi: 10.1158/1535-7163.MCT-13-0481. Epub 2014 Jan 7.

9.

Epidermotropic progression of melanoma during therapy with vemurafenib and trametinib.

Ferrara G, Cacitti V, Improta G, Lo Re G, Corradin MT.

J Am Acad Dermatol. 2016 Oct;75(4):e133-e135. doi: 10.1016/j.jaad.2016.03.006. No abstract available. Erratum in: J Am Acad Dermatol. 2017 Jan;76(1):189.

PMID:
27646754
10.

Development of Cutaneous Toxicities During Selective Anti-BRAF Therapies: Preventive Role of Combination with MEK Inhibitors.

Erfan G, Puig S, Carrera C, Arance A, Gaba L, Victoria I, Garcia-Herrera A, Alos L, Malvehy J.

Acta Derm Venereol. 2017 Feb 8;97(2):258-260. doi: 10.2340/00015555-2488. No abstract available.

11.

Phosphoproteomics of MAPK inhibition in BRAF-mutated cells and a role for the lethal synergism of dual BRAF and CK2 inhibition.

Parker R, Clifton-Bligh R, Molloy MP.

Mol Cancer Ther. 2014 Jul;13(7):1894-906. doi: 10.1158/1535-7163.MCT-13-0938. Epub 2014 May 13.

12.

[The Role of BRAF/MEK Inhibition in Metastatic Malignant Melanoma - a Case Study].

Kopecký J, Kubeček O.

Klin Onkol. 2016;29(2):133-8. Czech.

PMID:
27081804
13.

Clinical observation of panniculitis in two patients with BRAF-mutated metastatic melanoma treated with a combination of a BRAF inhibitor and a MEK inhibitor.

Galliker NA, Murer C, Kamarashev J, Dummer R, Goldinger SM.

Eur J Dermatol. 2015 Apr;25(2):177-80. doi: 10.1684/ejd.2014.2512.

PMID:
25788221
14.

Discussion.

[No authors listed]

J Am Coll Surg. 2015 Apr;220(4):593-5. doi: 10.1016/j.jamcollsurg.2015.01.025. No abstract available.

PMID:
25797744
15.

Improved overall survival in melanoma with combined dabrafenib and trametinib.

Robert C, Karaszewska B, Schachter J, Rutkowski P, Mackiewicz A, Stroiakovski D, Lichinitser M, Dummer R, Grange F, Mortier L, Chiarion-Sileni V, Drucis K, Krajsova I, Hauschild A, Lorigan P, Wolter P, Long GV, Flaherty K, Nathan P, Ribas A, Martin AM, Sun P, Crist W, Legos J, Rubin SD, Little SM, Schadendorf D.

N Engl J Med. 2015 Jan 1;372(1):30-9. doi: 10.1056/NEJMoa1412690. Epub 2014 Nov 16.

16.

Major clinical response to a BRAF inhibitor in a patient with a BRAF L597R-mutated melanoma.

Bahadoran P, Allegra M, Le Duff F, Long-Mira E, Hofman P, Giacchero D, Passeron T, Lacour JP, Ballotti R.

J Clin Oncol. 2013 Jul 1;31(19):e324-6. doi: 10.1200/JCO.2012.46.1061. Epub 2013 May 28. No abstract available.

PMID:
23715574
17.

BRAF and MEK inhibition variably affect GD2-specific chimeric antigen receptor (CAR) T-cell function in vitro.

Gargett T, Fraser CK, Dotti G, Yvon ES, Brown MP.

J Immunother. 2015 Jan;38(1):12-23. doi: 10.1097/CJI.0000000000000061.

PMID:
25415284
18.

Combination therapy approved for melanoma.

[No authors listed]

Cancer Discov. 2014 Mar;4(3):262. doi: 10.1158/2159-8290.CD-NB2014-013. Epub 2014 Jan 30.

19.

Successful (neo)adjuvant BRAF-targeted therapy in a patient with locally advanced BRAF V600E mutant melanoma.

Seremet T, Lienard D, Suppa M, Trepant AL, Rorive S, Woff E, Cuylits N, Jansen Y, Schreuer M, Del Marmol V, Neyns B.

Melanoma Res. 2015 Apr;25(2):180-3. doi: 10.1097/CMR.0000000000000145.

PMID:
25643238
20.

Cutaneous adverse events in patients treated with BRAF inhibitor-based therapies for metastatic melanoma for longer than 52 weeks.

Anforth R, Carlos G, Clements A, Kefford R, Fernandez-Peñas P.

Br J Dermatol. 2015 Jan;172(1):239-43. doi: 10.1111/bjd.13200. Epub 2014 Nov 21.

PMID:
25040674

Supplemental Content

Support Center